Cubicin Resistance Should Be Closely Monitored In Bacteremia Patients
Executive Summary
Labeling regarding use of Cubist's anti-infective Cubicin in Staphylococcus aureus patients should include a recommendation for close monitoring for development of resistance, members of FDA's Anti-Infective Drugs Advisory Committee said March 6